Floatz logo

112 assets in Hormone Receptor-Positive Breast Cancer

Therapeutic assets addressing Hormone Receptor-Positive Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Zanzalintinib
Hormone Receptor-Positive Breast Cancer
ExelixisP1CC (43)
Avelumab
Hormone Receptor-Positive Breast Cancer
ExelixisP1CC (42)
Cirtociclib
Hormone Receptor-Positive Breast Cancer
Blueprint Medicines CorporationP1CC (41)
Simvastatin
Hormone Receptor-Positive Breast Cancer
Emory UniversityEarly P1C (39)
sm-88
Hormone Receptor-Positive Breast Cancer
Georgetown UniversityP2C (36)
Lacudy
Hormone Receptor-Positive Breast Cancer
Gun Oh ChongN/AD (30)
Adriamycin
Hormone Receptor-Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP3NR ()
Mrt-2359
Hormone Receptor-Positive Breast Cancer
Monte Rosa Therapeutics, IncP1/2NR ()
ntq1062
Hormone Receptor-Positive Breast Cancer
Nanjing Chia-tai Tianqing PharmaceuticalP3NR ()
prt2527
Hormone Receptor-Positive Breast Cancer
Prelude TherapeuticsP1NR ()
sbt6290
Hormone Receptor-Positive Breast Cancer
Silverback TherapeuticsP1/2NR ()
Toremifene
Hormone Receptor-Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP2/3NR ()
Showing 101 to 112 of 112 assets
PreviousPage 3 of 3Next